Abstract
Patient-oriented outcome measures, such as symptoms, physical functioning, and health-related quality of life, are pertinent outcome measures for patients who cannot be cured of their disease. This is the case for virtually all patients with primary or metastatic brain tumors for whom palliation of symptoms and the maintenance or improvement of health-related quality of life are important goals of treatment earlier or later in the disease trajectory. Brain tumors greatly impact on an individual, as well as their family members and friends. The tumor or its treatment (i.e., chemotherapy, radiation, pharmacological treatment) may directly or indirectly cause neurological impairments that affect the physical, social, vocational, and emotional capabilities of the individual. The available treatment options for both primary and metastatic brain tumors have improved and brought with them modest improved patient survival. Evaluation of treatment in brain tumor patients should therefore not only focus on survival improvement, but should also aim at determining neurological functioning and adverse treatment effects on the normal brain. In this respect, neurocognitive functioning (NCF) is a highly critical outcome measure for brain tumor patients [1]. Apart from a prognostic significance of baseline NCF [2, 3], deterioration in NCF in brain tumor patients may herald tumor progression, even before signs of disease recurrence are evident on CT or MRI [4–6].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159–68.
Klein M, Postma TJ, Taphoorn MJB, et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology. 2003;61:1796–9.
Johnson DR, Sawyer AM, Meyers CA, O’Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro-oncology. 2012;14:808–16.
Armstrong CL, Goldstein B, Shera D, Ledakis GE, Tallent EM. The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer. 2003;97:649–56.
Brown PD, Jensen AW, Felten SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24:5427–33.
Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-oncology. 2003;5:89–95.
World Health Organization. International classification of functioning, disability and health: ICF. Geneva, Switzerland: WHO; 2001.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state for the clinician. J Psychiatric Res. 1975;12:189–98.
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatrics Soc. 2005;53:695–9.
Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, et al. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 2012;8:536–43.
Brennan L, Siderowf A, Rubright JD, et al. The Penn Parkinson’s daily activities questionnaire-15: psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson’s disease. Parkinsonism Relat Disord. 2016;25:21–6.
Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45:251–5.
Oort Q, Dirven L, Meijer W, et al. Development of a questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumors: a pilot study. J Neuro-Oncol. 2017;132:145–53.
Ustun TB, Chatterji S, Kostanjsek N, et al. Developing the World Health Organization disability assessment schedule 2.0. Bull World Health Organ. 2010;88:815–23.
Ownsworth T, Hawkes A, Steginga S, Walker D, Shum D. A biopsychosocial perspective on adjustment and quality of life following brain tumor: a systematic evaluation of the literature. Disabil Rehabil. 2009;31:1038–55.
Lidstone V, Butters E, Seed PT, et al. Symptoms and concerns amongst cancer outpatients: identifying the need for specialist palliative care. Palliat Med. 2003;17:588–95.
Syrjala KL, Stover AC, Yi JC, Artherholt SB, Abrams JR. Measuring social activities and social function in long-term cancer survivors who received hematopoietic stem cell transplantation. Psycho-Oncology. 2010;19:462–71.
Happold C, Felsberg J, Clarke J, et al. Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: first results from the Brain Tumor Funders’ Collaborative Consortium. In: 22nd annual scientific meeting and education day of the society for neuro-oncology. November 16–19 2017, San Francisco, CA.
Gilbert M, Armstrong T, Meyers C. Issues in assessing and interpreting quality of life in patients with malignant glioma. Semin Oncol. 2000;27:20–6.
Armstrong TS, Vera-Bolanos E, Acquaye AA, et al. The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. Neuro Oncology. 2016;18:252–60.
Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol. 2017;13:52–64.
Vannorsdall TD. Cognitive changes related to cancer therapy. Med Clin N Am. 2017;101:1115–34.
Bosma I, Vos MJ, Heimans JJ, et al. The course of neurocognitive functioning in high-grade glioma patients. Neuro-oncology. 2007;9:53–62.
Hassler MR, Elandt K, Preusser M, et al. Neurocognitive training in patients with high-grade glioma: a pilot study. J Neuro-Oncol. 2010;97:109–15.
Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol. 2009;27:3712–22.
Gehring K, Aaronson NK, Taphoorn MJ, Sitskoorn MM. Interventions for cognitive deficits in patients with a brain tumor: an update. Expert Rev Anticancer Ther. 2010;10:1779–95.
Boele FW, Zant M, Heine ECE, et al. The association between cognitive functioning and health-related quality of life in low-grade glioma patients. Neuro-Oncol Pract. 2014;1:40–6.
Cull A, Hay C, Love SB, et al. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996;74:1674–9.
Stewart AL, Ware JE, editors. Measuring functioning and well-being: the medical outcomes study approach. Durham, NC: Duke University Press; 1992.
Ediebah DE, Reijneveld JC, Taphoorn MJ, et al. Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res. 2017;26:869–80.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.
Bucks RS, Haworth J. Bristol activities of daily living scale: a critical evaluation. Expert Rev Neurother. 2002;2:669–76.
Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncology. 2016;18:1656–63.
Klein M. Lesion momentum as explanation for preoperative neurocognitive function in patients with malignant glioma. Neuro-oncology. 2016;18:1595–6.
Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007;18:1145–51.
Klein M, Taphoorn MJ, Heimans JJ, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001;19:4037–47.
Brown PD, Buckner JC, O'Fallon JR, et al. Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys. 2004;59:117–25.
Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21:3557–8.
Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. J Clin Oncol. 2004;22:966–7.
Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test–revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43–55.
Benton AL, Hamsher K. Multilingual aphasia examination. Iowa City: AJA Associates; 1989.
Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. New York: Oxford University Press; 2004.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Klein, M. (2019). Assessment of Neurocognitive Functioning in Clinical Practice and for Trial Purposes. In: Bartolo, M., Soffietti, R., Klein, M. (eds) Neurorehabilitation in Neuro-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95684-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-95684-8_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95683-1
Online ISBN: 978-3-319-95684-8
eBook Packages: MedicineMedicine (R0)